<DOC>
	<DOCNO>NCT02883894</DOCNO>
	<brief_summary>Bullous pemphigoid common subepidermal autoimmune blister disease skin European country , include France . Immunologically , BP characterize production autoantibody direct two major component hemidesmosome , BP180 BP230 . The anti-BP180 autoantibody detect 79-93 % case bullous pemphigoid serum level diagnosis correlate disease activity . The anti-BP230 autoantibody detect 57 % -63 % bullous pemphigoid case score diagnosis correlate disease activity . Up , clinical immunologic factor identify predict outcome patient good poor prognosis bullous pemphigoid define long complete remission therapy recurrent disease require maintenance therapy year . The usefulness BP180 BP230 ELISA score monitor BP patient treatment also remain unclear .</brief_summary>
	<brief_title>Interest Dosage Anti-PB230 , Anti-PB180 Cytokines Monitoring Patients Suffering From Bullous Pemphigoid</brief_title>
	<detailed_description>Aim study : To study association serum level cytokine ( IL-17 IL-23 ) protease MMP-9 relapse bullous pemphigoid .</detailed_description>
	<mesh_term>Pemphigoid , Bullous</mesh_term>
	<criteria>patient bullous pemphigoid patient yet receive treatment bullous pemphigoid age &gt; 18 year Patients relapse bullous pemphigoid</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
</DOC>